



## UTOPIAN Primary Care Trials Group — Session 15 *Minutes* Wednesday, May 27<sup>th</sup>, 2021, from 4:00 p.m. to 5:00 p.m., Zoom teleconference

Item	Topic	Minutes	Action	Responsible
1	Introductions (Andrew Pinto)	Andrew Pinto introduced those present via Zoom and on the phone		
2	Review and approval of March 31, 2021, draft meeting minutes (All)	Minutes of the previous meeting were approved by those present	Approved	All
3	Presentation: Actionable lessons from the CLEAN Meds RCT (Nav Persaud)	CLEAN Meds RCT - Study Rationale:  Life-saving treatments and other essential medicines are out of reach for some. Canada is the only high-income country in the world that publicly funds healthcare services but not medicines The purpose of the CLEAN Meds randomized controlled trial is to measure the effects of distributing essential medicines for free  Lessons for Primary Care Trialists:  Community engagement Codesigned by a community guidance panel Involving community members who have been affected or know someone who has been affect, proved to be extremely helpful in knowledge exchange with decision makers - i.e., it gives decisions makers confidence that the issue is important to people and that the study was done considering outcomes that were important to people who were affected  Tackling a Big Issue Make it count! - since a trial requires a lot of time intensive work to get the project funded, running and achieve results, make it count by focusing on a big issue.  E.g., CLEAN Meds RCT - 2-year trial = 7+ years of work Results can help inform public policy		

		Stories/Qualitative work Stories: allowed patients to tell their personal stories of how the interventions improved their access to medicine and some of the ways that impacted them. Early on, they opted for having a film crew follow a small number of patients (3 participants from the intervention group and 3 participants in the control group) To watch these videos, visit <a href="www.cleanmeds.ca">www.cleanmeds.ca</a> Telling patient stories through film has been very useful in communicating with decision makers and funders  Outcome primary care For the CLEAN Meds study, we were talking about adherence to medications that were proven to be effective (e.g., treatments for blood pressure or HIV/AIDS) where there is not a big controversy in whether or not people are better off if the take these medications There is a tradeoff in selecting a population that is a higher risk. The results are less generalizable Choosing a relatively healthy population poses a challenge for primary care trials because it is difficult to power a study to a health outcome like mortality, heart attacks or strokes and make it feasible. All the while, wanting to select an outcome that is important.  Building team Important to have affair and transparent process for deciding who is part of team E.g., Co-Investigators should be representative of the study population with respect to gender
4	Expansion to Ontario Primary Care Trials Network (Andrew Pinto)	POPLAR:  • The 7 PBLNs in primary care across Ontario have come together (6 academic PBLNs across departments of family medicine in Ontario and the Alliance for Healthier Communities – Ontario's CHCs)  • Purpose: to give rise to a provincial EMR database that will support research efforts for QI and health systems study  • Funded by the Ministry of Health  • Shared leadership across 7 networks  • Andrew and Dee Mangin co-chair the Clinical Research Group  Ontario Primary Care Trials Network:  • Starting in the Fall of 2021, we will expand the PCTG to include members from the other networks. This group will become the Ontario Primary Care Trials Network  • Goals:  • Better efficiency, increasing the number of clinics that are research ready to engage in trials and more connections between investigators  • All the while maintaining the principles that guide our work: research studies are of importance to

		primary care, are answering important primary care questions, are engaging and build capacity					
5	Clinical Trials update (Aashka Bhatt)	<ul> <li>SARTAN-AD:         <ul> <li>Looks at the hypertensive medications proving protective benefits in slowing down Alzheimer's disease (and mild to moderate cognitive decline)</li> <li>We have updated the new protocol and eligibility criteria</li> <li>Currently, reconsenting physicians at UTOPIAN sites to increase our patient recruitment numbers</li> </ul> </li> <li>Advanced Care Planning (ACP):         <ul> <li>Recruitment is closed. UTOPIAN recruited 125 patients to this project</li> <li>Received a 9-month extension and additional funding awarded by PCORI to help understand how to sustain ACP practices at participating sites and how to engage patient partners further in dissemination activities</li> </ul> </li> <li>SPIDER:         <ul> <li>Feasibility phase was in Toronto, the RCT phase is managed by OPEN (Ottawa)</li> <li>Considering running this through POPLAR as the</li> </ul> </li> </ul>					
Maa	ting adjourned at F.O	learning collaborative is now virtual					
	Meeting adjourned at 5:00 p.m.  Nort meeting June 17, 2021; 4:00 p.m. (virtual)						
Nex	Next meeting: June 17, 2021; 4:00 p.m5:00 p.m. (virtual)						